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A promising strategy to investigate the role of inﬂammation in
schizophrenia (SZ) is to focus on a special type of cytokines involved
in the attraction of cells to the inﬂammatory site, such as the
chemokines CXCL-10/IP-10, CXCL-8/IL-8, CCL-11/Eotaxin, CCL-24/
Eotaxin-2, CCL-2/MCP-1, and CCL-3/MIP-1 (Potvin et al., 2008; Miller
et al., 2011). Evidence points towards an interaction between chemo-
kine and neurotransmitter systems in the brain, playing crucial roles
in brain development and function (Capuron andMiller, 2011). Beyond
that, chemokines have been suggested as potentially useful biomarkers
in psychiatric disorders such as SZ (Reale et al., 2011) commonly
associated to accelerated biological aging (Porton et al., 2008). Increased
CCL-11 serum levels togetherwith impaired neurogenesis in hippocam-
pus were seen in young mice after infusion of plasma from old mice
(Villeda et al., 2011) Nevertheless, only few studies have evaluated
the role of chemokines in the neurobiology of SZ (Teixeira et al., 2008;
Reale et al., 2011).
Since understanding the role of trait disease biomarkers in SZ could
potentially open new staging possibilities in order to personalize, opti-
mize and improve treatments, the aim of this study was to investigate
serum levels of two chemokines: CCL-11 (Eotaxin) and CCL-24
(Eotaxin-2), in recent onset (RO) and chronic patients (CP) with SZ in
symptomatic remission.
Methods have been described elsewhere (Teixeira et al., 2008;
Pedrini et al., 2012). Forty-two outpatients with SZ and thirty-seven
healthy controls matched for age, gender, body mass index and level
of education were recruited. The double case–control design included
23 RO patients (within ﬁrst 5 years of SZ diagnosis), 19 CP (minimum
of 20 years after the diagnosis of SZ) and their respective matched con-
trols (19 and 18 subjects). Symptomatic remission was deﬁned as BPRS
scores below15. All subjects had blood samples collected between 2 pm
and 4 pm.
The subjects' characteristics are summarized in Table 1.
CCL-24 serum levels were signiﬁcantly higher in RO (p = 0.010)
and CP (p = 0.034) with SZ compared to controls. CCL-11 serum levels
were not different in RO (p = 0.806) and increased in CP (p = 0.001)
compared to controls. There was no signiﬁcant correlation between
age and CCL-11 in controls (p = 0.225; rho = −0.204) and all groups
together (p = 0.225; rho = −0.204), and a correlation trend in pa-
tients (p = 0.081; rho = 0.303). There was a correlation trend be-
tween illness duration and CCL-11 levels (p = 0.093; rho = 0.293).0920-9964 © 2013 The Authors. Published by Elsevier B.V.
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Open access under CC BY-NC-ND licTo our knowledge, this is the ﬁrst study to examine serum chemo-
kine levels in a sample of two groups of patients with SZ, differing in ill-
ness duration: 2.88 (1.86) years for RO and 25.61 (4.79) years for CP.
This study shows that CCL-11 and CCL-24 serum levels were
increased in CP when compared to controls. Regarding RO patients,
CCL-24 levels were also increased, but CCL-11 levels were not different
from controls.
In a recent preclinical study, the infusion of plasma from old mice to
young ones led to increased plasma levels of CCL-11 in the young mice
(Villeda et al., 2011). Thus, Villeda's study reached to the interesting, but
yet speculative conclusion that this chemokine could be associated to
hippocampus neurogenesis impairment and brain aging (Villeda et al.,
2011). In addition, it has been shown that increased CCL-11 serum
levels in individuals with SZ are inversely correlated to performance
in working memory test (Asevedo et al., 2013). It has also been
established that CCL-11 increases with age in both humans and rodents
(Fernandez-Egea et al., 2013).
This study designwas cross-sectional; it did not allow us a direct ex-
amination of the course of chemokines in SZ, only differences between
controls and patients in different phases of SZ. The inclusion of two con-
trol groups matched to RO and chronic stage groups allowed differenti-
ation of age, sex, body mass index and diagnosis effects. The effect of
cigarette smoking on serum biomarkers could not be excluded, howev-
er there were no differences in number of cigarettes smoked a day be-
tween groups. Although the effect of medication could not also be
excluded, it has been reported that antipsychotics would decrease cen-
tral and peripheral inﬂammation (Miller et al., 2011).
Supporting the hypothesis that SZ is associated with a pro-
inﬂammatory activation, this study importantly suggests that higher
levels of serum peripheral CCL-11 are increased in patients with more
than 20 years of disease compared to their controls, at least in this co-
hort; and might be a trait biomarker for accelerated aging process that
occurs in SZ. This is probably related to a greater inﬂammatory activa-
tion, impaired functionality, increased mortality, and to other clinical
diseases that overlap in patients with SZ. Additional studies relating
telomere shortening with CCL-11 would be helpful in giving a sharper
answer about the role of CCL-11 in SZ as a possible trait biomarker.
Discovering this chemokine's role and adopting a clinical staging
model approach are particularly useful and may help to prevent the
pathological aging consequences and optimize treatment strategies for
this condition.
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Table 1
Characteristics of healthy controls and patients with schizophrenia.
Recent onset (RO) Chronic patients (CP)
SZ (n = 23) Controls (n = 19) p-Value SZ (n = 19) Controls (n = 18) p-Value
Gender (male/female) 13/10 10/9 0.523a 15/4 13/5 0.714a
Age in yearsb 24.70 (4.78) 25.32 (5.19) 0.692c 47.47 (3.41) 46.89 (4.28) 0.650c
Years of educationb 10.17 (2.57) 11.32 (1.99) 0.112c 10.26 (3.23) 10.39 (3.22) 0.906c
Years of diseaseb 2.52 (1.83) – – 25.63 (4.66) – –
Number of cigarettes a day
None 22 23 0.358a 17 17 0.580a
Less than 10 1 0 2 1
Antipsychotic daily dose, in mg of chlorpromazine equivalentsb 400 (194.24) – – 624 (203.01) – –
Body mass indexb 25.05 (5.19) 26.31 (5.17) 0.426c 26.66 (2.64) 26.24 (5.46) 0.768c
BPRS total scoresd 14 (10) – – 13 (9) – –
CCL11d 775.01 (1215.23) 837.04 (696.79) 0.806e 1294.18 (2064.21) 614.59 (726.42) 0.001e
CCL24d 5440.03 (5081.67) 3668.58 (2952.29) 0.010e 5382.73 (5676.92) 3087.08 (2947.88) 0.034e
a Chi-square.
b Mean (standard deviation).
c T-test.
d Median (interquartile range).
e Mann–Whitney.
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